CN116870121A - Traditional Chinese medicine composition for treating double heart disease and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating double heart disease and preparation method and application thereof Download PDFInfo
- Publication number
- CN116870121A CN116870121A CN202311044497.2A CN202311044497A CN116870121A CN 116870121 A CN116870121 A CN 116870121A CN 202311044497 A CN202311044497 A CN 202311044497A CN 116870121 A CN116870121 A CN 116870121A
- Authority
- CN
- China
- Prior art keywords
- parts
- heart disease
- treating
- traditional chinese
- double heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 93
- 208000019622 heart disease Diseases 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 241000202726 Bupleurum Species 0.000 claims abstract description 14
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 14
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 14
- 238000005303 weighing Methods 0.000 claims abstract description 6
- 244000132619 red sage Species 0.000 claims abstract description 3
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims abstract 2
- 244000163122 Curcuma domestica Species 0.000 claims abstract 2
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract 2
- 235000003373 curcuma longa Nutrition 0.000 claims abstract 2
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 claims abstract 2
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000013976 turmeric Nutrition 0.000 claims abstract 2
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 13
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 13
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 12
- 244000141009 Hypericum perforatum Species 0.000 claims description 12
- 244000197580 Poria cocos Species 0.000 claims description 11
- 235000008599 Poria cocos Nutrition 0.000 claims description 11
- 240000007164 Salvia officinalis Species 0.000 claims description 11
- 235000017276 Salvia Nutrition 0.000 claims description 9
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 241000207929 Scutellaria Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 abstract description 36
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 27
- 230000036407 pain Effects 0.000 abstract description 13
- 206010008479 Chest Pain Diseases 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 9
- 206010013954 Dysphoria Diseases 0.000 abstract description 7
- 235000019658 bitter taste Nutrition 0.000 abstract description 7
- 206010033557 Palpitations Diseases 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 5
- 206010022437 insomnia Diseases 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 4
- 230000002936 tranquilizing effect Effects 0.000 abstract description 4
- 208000000059 Dyspnea Diseases 0.000 abstract description 3
- 206010013975 Dyspnoeas Diseases 0.000 abstract description 3
- 206010022998 Irritability Diseases 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 208000013220 shortness of breath Diseases 0.000 abstract description 2
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 28
- 241000700159 Rattus Species 0.000 description 27
- 208000019901 Anxiety disease Diseases 0.000 description 17
- 208000010125 myocardial infarction Diseases 0.000 description 17
- 230000036506 anxiety Effects 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 12
- 210000001320 hippocampus Anatomy 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000002107 myocardial effect Effects 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 8
- 230000000971 hippocampal effect Effects 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000004217 heart function Effects 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000003012 network analysis Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010013789 Dry throat Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000006400 anxiety behaviour Effects 0.000 description 2
- 238000013542 behavioral therapy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 101000831205 Danio rerio Dynein axonemal assembly factor 11 Proteins 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102100024282 Dynein axonemal assembly factor 11 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241001559542 Hippocampus hippocampus Species 0.000 description 1
- 101000831210 Homo sapiens Dynein axonemal assembly factor 11 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
A Chinese medicinal composition for treating double heart disease is prepared from the following Chinese medicaments in part by weight: 6-24 parts of bupleurum, 5-20 parts of baical skullcap root, 5-20 parts of danshen root, 5-20 parts of turmeric root-tuber, 8-32 parts of Indian buead, 5-20 parts of cassia twig and 10-30 parts of hyperforin herb, and the preparation method comprises the following steps: weighing the above medicines according to the weight ratio, adding water which is 5-10 times of the total weight of the medicines for decoction for 1-3 times, combining the decoction and concentrating to 1/3-1/2 of the water adding amount, thus obtaining the traditional Chinese medicine. The composition fully plays the effects of soothing liver, relieving depression, promoting blood circulation, dredging collaterals, clearing heat and tranquillizing, treats chest distress, heart pain, palpitation, dysphoria, irritability, shortness of breath, insomnia, dreaminess, bitter taste and other symptoms caused by heart vessel stasis, qi and blood imbalance and internal disturbance, is compatible with the characteristics and advantages of overall regulation, multiple targets, multiple mechanisms, less side effects and low price of the double heart disease, and has good economic and social significance in preventing and treating the occurrence and development of the double heart disease.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating double heart diseases, and a preparation method and application thereof.
Background
Double heart disease refers to cardiovascular diseases combined with mental and psychological diseases, which are mainly manifested by common pathogenicity of heart and mind, and the two are closely related and mutually influenced [1] . Cardiovascular diseases belong to the categories of chest stuffiness and pains and mental and psychological diseases belong to the categories of depression and dysphoria in traditional Chinese medicine.
In recent years, the incidence rate of the double heart disease is increased greatly, and the physical and psychological health of the national people is seriously threatened [3 -5]. Cardiovascular problems are an important global health problem, and the occurrence and development of cardiovascular diseases are closely related to mood swings, and several epidemiological studies suggest that anxiety in patients with coronary heart disease is high in proportion to 45.8% [6,7] . And anxiety and depression are important causes of cardiac death, severely affecting disease prognosis [8] 。
At present, for the treatment of the double heart diseases, the combined application mode of cardiovascular drugs and antidepressant anxiety drugs is still adopted clinically, for example, 5-hydroxytryptamine reuptake inhibitor is combined on basic drugs of cardiovascular diseases, but the depression can be improved to a certain extent [10] However, the effect on the long-term prognosis of heart is still controversial, and the antidepressant anxiety drugs have corresponding adverse reactions [11] . In addition, cognitive behavior therapy is used as a first-line treatment method for the double heart disease, but the cognitive behavior therapy is time-consuming, high in cost and less in influence on cardiovascular events, and the overall curative effect still needs to be optimized by combining medicines, exercises and the like [12] . In a new bio-social-psychological medicine mode, although some scholars propose the treatment of the double heart disease of traditional Chinese medicine, the clinical effect is poor, and deep and rigorous basic and clinical researches are lacking, so that deep excavation is still needed in the current researchesTherapeutic drug with clinical efficacy [13] . The clinical research of the double heart medical diagnosis and treatment mode has led to great progress, but the clinical lack of effective targeted therapeutic drugs has generally low cure rate, which causes the clinical treatment of the double heart disease to be in the bottleneck, and the development of clinically effective therapeutic drugs is urgently needed [9] 。
Disclosure of Invention
Aiming at clinical manifestations of double heart disease: the method has the advantages that symptoms such as chest distress, heart pain, palpitation, dysphoria, irritability, depression, shortness of breath, insomnia, dreaminess, bitter taste and the like are suggested to be treated by the syndrome treatment rule, under the guidance of the overall viewing principle of traditional Chinese medicine, the two symptom problems of the double heart disease are combined into one, the syndrome and the syndrome are combined, the past diagnosis and treatment prescription and clinical proved prescription aiming at the double heart disease are optimized, the basic prescription for treating the double heart disease is refined, the effective rate of treating the double heart disease can be remarkably improved by the prescription, and the unique advantage of treating the double heart disease by the traditional Chinese medicine is fully embodied.
The invention provides a traditional Chinese medicine composition for treating double heart diseases, which is prepared from the following traditional Chinese medicines in parts by weight: 6-24 parts of bupleurum, 5-20 parts of scutellaria baicalensis, 5-20 parts of red sage root, 5-20 parts of radix curcumae, 8-32 parts of poria cocos, 5-20 parts of cassia twig and 10-30 parts of hypericum perforatum;
further, the Chinese medicinal composition for treating the double heart disease is prepared from the following Chinese medicaments in part by weight: 6 parts of bupleurum, 5 parts of scutellaria baicalensis, 5 parts of red-rooted salvia root, 5 parts of radix curcumae, 8 parts of poria cocos, 5 parts of cassia twig and 10 parts of hypericum perforatum;
further, the Chinese medicinal composition for treating the double heart disease is prepared from the following Chinese medicaments in part by weight: 24 parts of bupleurum, 20 parts of scutellaria baicalensis, 20 parts of red-rooted salvia root, 20 parts of radix curcumae, 32 parts of poria cocos, 20 parts of cassia twig and 30 parts of hypericum perforatum;
further, the Chinese medicinal composition for treating the double heart disease is prepared from the following Chinese medicaments in part by weight: 12 parts of bupleurum, 10 parts of scutellaria baicalensis, 10 parts of red-rooted salvia root, 10 parts of radix curcumae, 16 parts of poria cocos, 10 parts of cassia twig and 20 parts of hypericum perforatum;
the second aspect of the invention provides a preparation method of any one of the above Chinese medicinal compositions for treating double heart disease, which comprises the following steps of: weighing the above medicines according to the weight ratio, adding water which is 5-10 times of the total weight of the medicines for decoction for 1-3 times, combining the decoction and concentrating to 1/3-1/2 of the water adding amount to obtain the traditional Chinese medicine;
the third aspect of the invention provides a medicament for treating double heart disease, which comprises any one of the traditional Chinese medicine composition and a pharmaceutically acceptable carrier;
further, the medicine is an oral preparation or an injection.
The fourth aspect of the invention provides application of any one of the above traditional Chinese medicine composition in preparing medicines for treating double heart diseases.
Drawings
FIG. 1 reflects a comparison of cardiac ultrasound and cardiac functional parameters for each group of rats
FIG. 2 is a graph showing a comparison of results of the open field experiments and the elevated plus maze experiments for each group of rats
FIG. 3 reflects a comparison of neurotransmitter levels in the hippocampus of each group of rats
FIG. 4 reflects the results of HE staining, hippocampus Nib staining, and Masson staining of myocardium of rats in each group
FIG. 5 identification of differentially expressed proteins in heart tissue of myocardial infarction border region in different groups of rats
FIG. 6 identification of differentially expressed proteins in hippocampus of different groups of rats
FIG. 7 PPI-hub network analysis of myocardial infarction border area and hippocampal sham-model group differential protein
FIG. 8GO and KEGG analysis results
Advantageous effects
A large number of clinical syndrome researches prove that 'blood stasis and heat deficiency stagnation' is the main pathogenesis of the occurrence and development of the double heart disease, wherein blood stasis is the onset, heat is gradually changed, deficiency is the pivot, and stagnation is changed. Stasis, i.e. stagnant blood in the heart vessels, is the initiating factor in the formation of double heart disease. The heart governs blood vessels, so-called "all blood vessels" belong to the heart "(" Su and Wu Zong Cheng Fang ", the" heart, sheng Ben, shen Ding also, its surface is the surface, it fills in blood vessels "(" Su and Liu Jie Zangxiang Lun ")", the heart can regulate the running of blood and the smoothness of the veins; as for heart-qi, the principal sense is also the heart-qi, which is known from "Su Wen-Ling lan Mi Dian Lun", and the heart-qi, which is the principal of the five zang organs and six fu organs, can coordinate the mental consciousness of the person. The blood stasis penetrates through the double heart disease all the time, is a basic pathological factor formed by the double heart disease, is mutually combined with various pathological products, blocks heart vessels, blood flow stagnation, and causes chest distress and pain, fixed pain, anxiety depression, insomnia, memory decline and the like due to the fact that the heart of the blood vessels and the heart of the mind cannot be nourished. Heat, i.e. endogenous pathogenic heat, is the pathological factor that causes the gradual change of the double heart disease. Excessive qi is fire, extreme emotion, internal heat and blaze burning heart vessels, disturbing the mind upwards, just like "heart is fire, candelapsing things, so the mind is clear" in blood syndrome theory and visceral disease theory; for a long time, the blood stasis and heat are removed, and the blood vessels are not going to run, but are heat (Ling Shu-Wu Chang), the blood is not going to run, stagnates blood vessels, stagnates and transforms heat, and the heart vessels are not going to be in an outer-heat-disturbing state, and the heart vessels are in an inner-heat-disturbing state, which are manifested as palpitation, chest burning pain, vexation and irritability, insomnia, red tongue with yellow and greasy coating, slippery and rapid pulse, etc. Deficiency, i.e. deficiency of qi and blood, is the pivot mechanism for transformation of deficiency and excess of double heart disease. "blood theory of symptoms and signs, hematemesis" cloud: when old blood is not removed, new blood is not generated. The blood stasis blockage can not be removed for a long time, and the qi and blood are damaged, the healthy qi is gradually deficient, and the pathogenesis is transformed from excess to deficiency. So-called "healthy qi is stored in the body, pathogenic qi cannot be dried", qi and blood deficiency failing to expel pathogenic factors can also cause stagnation of blood stasis and turbid phlegm due to deficiency and excess. Qi and blood deficiency means that the pulse is dry and astringent, the heart is not nourished and the spirit is not clear, as in the book "blood vessels and benefiting, spirit are the same as those of the book of Ling Shu-Ping ren Ji", heart failure to nourish the heart vessels means heart diseases and mind failure to nourish the mind means heart diseases. Stagnation, i.e. qi stagnation and phlegm obstruction, is an important pathological factor affecting the changes of the double heart disease, and stagnation of qi, heat and deficiency can lead to stagnation of qi, internal stagnation of phlegm-dampness, thereby aggravating the pathological changes of blood stasis, heat and deficiency. Stagnant blood causes stagnation of qi and water, which results in accumulation of phlegm and blood stasis, and qi movement of the whole body is not smooth to cause various diseases. For the understanding of the pathogenesis of the double heart disease of 'blood stasis and heat deficiency type', the traditional Chinese medicine composition with the basic treatment principles of activating blood circulation to dissipate blood stasis, promoting qi circulation to remove dampness, clearing heat and soothing the nerves is provided, and the traditional Chinese medicine composition aims at the diagnosis and treatment of individual symptoms of clinical patients, improves the life quality of the patients, has the advantages of low price and less side effect, and can treat and prevent the occurrence and development of the double heart disease as soon as possible and as soon as possible.
The Chinese medicinal composition has the advantages of pungent and bitter flavor, slight cold property, liver and gall meridian entered, and effects of clearing pathogenic qi of shaoyang, dispelling qi stagnation, relieving exterior and interior, soothing liver and relieving depression. "Shennong Ben Cao Jing" means that: the accumulation of food and drink, accumulation of pathogenic cold and heat, and promotion of new food. Baical skullcap root is bitter and cold, enters heart and lung meridians, has the effects of clearing heat and drying dampness, purging pathogenic fire and removing toxin, and can clear away less Yang Zhi heat. "Pearl bag" called Baikal skullcap root: the composition has the effects of removing excessive yang, cooling the heart, removing heat and expelling cold. "Bupleurum and baikal skullcap root are monarch drugs, one of them is dispersed, one of them is clear, and the other is just entering shaoyang, to relieve the pathogenic factors of shaoyang.Dan Shen is bitter in flavor and slightly cold in nature, enters heart and liver meridians. Has effects of removing blood stasis, relieving pain, promoting blood circulation, dredging channels, clearing heart fire, and relieving restlessness. Radix Salviae Miltiorrhizae in Shennong Ben Cao Jing: the pathogenic qi in the heart and abdomen is dominant, the borygmus is faint, such as water running, cold and heat accumulation, symptoms are broken, the abdominal mass is removed, restlessness is stopped, and qi is benefited. Yu jin is pungent and bitter in flavor and cold in nature, and enters heart, liver and lung meridians. Has the effects of activating blood and relieving pain, promoting qi and resolving depression, clearing away heart-fire and cooling blood, and promoting bile flow and removing jaundice, and is firstly carried out in the theory of medicine: for female blood stagnation, qi and heart pain, cold accumulation and Wen Cuma. "Salvia Miltiorrhiza and radix Curcumae are used as ministerial drugsPromoting blood circulation to remove blood stasis, clearing away heart-fire and tranquillizing. Poria is sweet and bland, neutral in nature, enters heart, spleen, lung and kidney meridians. Has effects of promoting diuresis, removing dampness, calming heart, tranquilizing mind, invigorating spleen and protecting kidney. The Shennong Ben Cao Jing records Poria as follows: the main chest and rib are reverse to qi, worry , frightening evil, palpitation, heart pain, dysphoria with cold and heat, cough and reverse, mouth Jiao Shegan and urination. Gui Zhi is pungent and sweet in nature and warm in nature, and enters heart, lung and bladder meridians. Has effects of inducing sweat, relieving muscle, warming and activating meridian, supporting yang, activating qi-flowing, and calming the pulse. Shennong Ben Cao Jing (Shennong's herbal medicine book) records cassia twig: for cough with dyspnea, stagnation of qi, pharyngitis, vomiting and suction, benefiting joints, strengthening middle-jiao and replenishing qi. "Ramulus Cinnamomi The combination of the Chinese medicinal materials with the poria and the Chinese medicinal materials has the effects of warming yang and promoting the circulation of water。Hypericum perforatum as guiding drugHas effects of dispersing stagnated liver qi, inducing resuscitation, relieving qi stagnation, clearing heat, eliminating dampness, and tranquilizing. Chinese pharmacopoeia: herba Hyperici perforati, pungent and cold, enters liver meridian. Liver soothing, qi stagnation relieving, heat clearing, dampness removing, repercussive and lactation promoting. Can be used for treating stagnation of liver-qi, depression, chest distress, joint swelling and pain, acute mastitis, and hypogalactia. "
Therefore, the composition fully plays the effects of soothing liver, relieving depression, promoting blood circulation, activating vessels, clearing heat and soothing nerves, treats chest distress, heart pain, palpitation, severe palpitation, dysphoria, short breath, insomnia, dreaminess, bitter taste and other symptoms caused by heart vessel stasis, qi and blood imbalance and internal disturbance, has the characteristics and advantages of overall regulation, multiple targets, multiple mechanisms, fewer side effects and low price when being matched with the double heart disease, and has good economic and social significance in preventing and treating the occurrence and development of the double heart disease.
Whether from gene level, animal experiment or clinical experiment index detection, the formula can obviously reduce various indexes of the double heart disease model animal, and can improve the heart function, emotion and behavior of the model animal by regulating and controlling the level of the hemoglobin complex and the activity of the oxygen carrier; obviously improves heart and mental symptoms such as chest distress and pain, vexation and dysphoria, dizziness, bitter taste in chest and hypochondrium, bitter taste in mouth and dry throat and the like of patients with the double heart disease, improves anxiety-like behaviors and states, has the effects of resisting inflammation and repairing myocardial cells and neuron cells, and can treat the double heart disease.
Detailed Description
Example 1
A Chinese medicinal composition for treating double heart disease is prepared from the following Chinese medicaments in part by weight: 6g of bupleurum, 5g of scutellaria baicalensis, 5g of red-rooted salvia root, 5g of radix curcumae, 8g of poria cocos, 5g of cassia twig and 10g of hypericum perforatum, and the preparation method of the traditional Chinese medicine composition comprises the following steps: weighing the above medicines according to the weight ratio, adding water which is 6 times of the total weight of the medicines, decocting for 3 times, combining the decoctions, and concentrating to 1/3 of the water adding amount.
Example 2
A Chinese medicinal composition for treating double heart disease is prepared from the following Chinese medicaments in part by weight: 24g of bupleurum, 20g of scutellaria baicalensis, 20g of red-rooted salvia root, 20g of radix curcumae, 32g of poria cocos, 20g of cassia twig and 30g of hypericum perforatum; the preparation method of the traditional Chinese medicine composition comprises the following steps: weighing the above medicines according to the weight ratio, adding water 10 times of the total weight of the medicines, decocting for 2 times, mixing decoctions, and concentrating to 1/2 of the water adding amount.
Example 3
A Chinese medicinal composition for treating double heart disease is prepared from the following Chinese medicaments in part by weight: the traditional Chinese medicine composition for treating the double heart disease is prepared from the following traditional Chinese medicines in parts by weight: 12g of bupleurum, 10g of scutellaria baicalensis, 10g of red-rooted salvia root, 10g of radix curcumae, 16g of poria cocos, 10g of cassia twig and 20g of hypericum perforatum; the preparation method of the traditional Chinese medicine composition comprises the following steps: weighing the above medicines according to the weight ratio, adding water which is 8 times of the total weight of the medicines, decocting for 2 times, combining the decoctions, and concentrating to 1/3 of the water adding amount.
Experimental example
Taking example 3 as an example of the administration group, the following experimental results were obtained:
experimental example 1: mechanism research for regulating hemoglobin complex level and improving myocardial infarction and anxiety-combined rats by using traditional Chinese medicine composition and oxygen carrier activity
SPF-grade male SD (SpragueDawley, SD) rats were selected for this experimental study. The 18 SD rats are divided into a sham operation group (only threading left anterior descending coronary artery is not ligated), a model group (ligating left anterior descending coronary artery and unpredictable empty bottle stimulation) and a traditional Chinese medicine group (composition of the invention), whether the myocardial infarction rats are successfully modeled or not is evaluated by adopting an electrocardiogram, the heart function of the rats is detected by heart ultrasonic, the behaviors of the rats are evaluated by overhead cross maze and open field tests, the morphology change of tissue cells is observed by HE, nile and Masson staining, and proteomics analysis is carried out on the boundary area around the infarction and the sea horse body by means of a protein non-marking quantitative technology.
Figure 1 reflects that the left ventricular ejection fraction (LVEF%, figure 1 d) and the left ventricular short axis shortening rate (LVFS%, figure 1 e) were significantly reduced, and the differences were statistically significant (P < 0.05), compared to the sham-operated group (figure 1 a). In contrast, the increase in LVEF% and LVFS% in the traditional Chinese group (fig. 1 c) compared to the model group indicates that the traditional Chinese composition can improve heart function in the model rats.
FIG. 2 and Table 1 show that the results of the open field experiments show that the horizontal motor scores of rats in the model group (FIG. 2 b) are reduced, the motor ability is reduced, but the differences are not statistically significant (P > 0.05) compared to the sham group (FIG. 2 a); compared with the model group (fig. 2 b), the horizontal movement score of the rats in the traditional Chinese medicine group (fig. 2 c) is increased, more active behaviors are shown, and the difference has statistical significance (P < 0.05). The results of the overhead plus maze experiment show that compared with the sham operation group (figure 2 e), the time that the rats in the model group (figure 2 f) stay on the open arm is obviously reduced; compared with the model group (figure 2 f), the time that the rats in the traditional Chinese medicine group (figure 2 g) stay in the open arm is obviously increased, the number of times of entering the open arm is obviously increased, and the difference has statistical significance (P < 0.05), which indicates that the rats in the traditional Chinese medicine group are more prone to stay in the open arm, and the traditional Chinese medicine composition can improve the anxiety behavior of rats with myocardial infarction and anxiety.
Table 1 results of the various groups of rat mine and elevated plus maze tests
FIG. 3, table 2, shows that the anxiety-related neurotransmitter GABA (FIG. 3 a) was significantly reduced in the hippocampus of the model group rats compared to the sham surgery group, and that the 5-HT (FIG. 3 b) level was significantly increased (P < 0.05), indicating that anxiety aggravates the disorder of synthetic secretion of neurotransmitter after myocardial infarction. Compared to the model group, the rat hippocampal GABA (FIG. 3 a) was significantly increased and 5-HT (FIG. 3 b) was significantly decreased (P < 0.05) in the traditional Chinese group. The traditional Chinese medicine composition can obviously reduce the synthesis disorder of hippocampal neurotransmitter function after myocardial infarction and improve anxiety.
TABLE 2 hippocampal neurotransmitter levels
FIG. 4 shows that HE staining shows that the myocardial fibers of the sham surgery group (FIG. 4 a) are aligned, the nuclei are regular, and the cytoplasm is stained uniformly. In contrast, the myocardial fiber arrangement disorder of the model group (fig. 4 b) occurs large-area cell necrosis loss, inflammatory infiltration of a large number of aggregated neutrophils and the like, the cytoskeletal structure disappears, and the muscle cell degradation is serious. The traditional Chinese medicine group (figure 4 c) reduces inflammatory infiltration in the border area of myocardial infarction and reduces myocardial infarction area. The Nile staining showed that the model group (FIG. 4 e) had fewer Nile bodies and the hippocampal DG region was more loosely arranged than the sham group (FIG. 4 d). The above changes were alleviated by the group of traditional Chinese medicines (fig. 4 f), demonstrating that the traditional Chinese medicine composition is helpful for the increase or recovery of nissan. The Masson staining results showed that the model group (FIG. 4 i) and the traditional Chinese medicine group (FIG. 4 j) showed more myocardial collagen fibrosis than the sham-operated group (FIG. 4 h), and that the fibrous scar formed and the myocardial fibrosis was severe. Quantitative analysis shows that the collagen areas of the model group and the traditional Chinese medicine group are larger than those of the sham operation group, and the traditional Chinese medicine can reduce the change (P is less than 0.05). The traditional Chinese medicine composition can improve myocardial injury and anxiety emotion of rats with myocardial infarction and anxiety.
FIG. 5 is a graph showing global clustered thermogram analysis of myocardium in FIG. 5a, myocardial pseudo-surgery set-model set comparison in FIG. 5b, and myocardial model set-traditional Chinese medicine set comparison in FIG. 5 c. In the identification results of the differential expression proteins in the heart tissues of the myocardial infarction marginal areas of rats in different groups, 253 differential expression proteins exist between the artificial operation group and the model group, wherein 138 differential expression proteins have a descending trend, and 115 differential expression proteins have an ascending trend. Meanwhile, 126 proteins are obviously changed between the model group and the traditional Chinese medicine group, wherein 64 proteins are down-regulated, and 62 proteins are up-regulated.
FIG. 6 shows that in the results of differential protein expression identification in different groups of hippocampus, 102 proteins were significantly altered in the hippocampus of the model group compared to the sham group, with 58 DEP expression decreased and 44 protein expression increased. Meanwhile, 108 differentially expressed proteins were identified between model and traditional Chinese medicine groups, 64 of which were down-regulated and 44 of which were up-regulated. Fig. 6a is a global cluster thermogram analysis of the hippocampus, fig. 6b is a sham-model group of the hippocampus, and fig. 6c is a hippocampus-model group of the traditional Chinese medicine.
Fig. 7 shows that fig. 7a is a graph of myocardial infarction border zone model group-traditional Chinese medicine group differential protein PPI-hub network analysis, and fig. 7b is a graph of hippocampal zone model group-traditional Chinese medicine group differential protein PPI-hub network analysis. The 126 different proteins in the model group and the traditional Chinese medicine group of the infarct edge zone comprise 39 nodes and 44 paths, 20 proteins with the highest association Degree (Degre) in the interaction relation are taken to make PPI again, and 20 nodes and 32 paths are obtained; likewise, 102 total differential proteins in the sham surgery and model groups in the hippocampus, comprising 15 nodes, 12 paths; 108 different proteins, 15 nodes and 9 paths in the model group and the traditional Chinese medicine group.
FIG. 8 shows that FIGS. 8a, b show general anxiety in the hippocampus and model group GO analysis, model group and traditional Chinese medicine group differential protein GO analysis, respectively; FIGS. 8c and d show general anxiety and model group GO analysis and model group and traditional Chinese medicine group differential protein GO analysis, respectively, of myocardial infarction areas; FIGS. 8e and f show the differential protein KEGG analysis of the sham-surgery group and model group, and the differential protein KEGG analysis of the model group and traditional Chinese medicine group, respectively; FIGS. 8g and h show the sham-operated and model-group differential protein KEGG analysis model group and traditional Chinese medicine-group differential protein KEGG analysis, respectively, of the hippocampus. Compared with the common anxiety rats, the differential protein of the myocardial infarction anxiety rats in the hippocampus is mainly involved in the regulation and control of neurotransmitter and receptor metabolism and transport processes, nerve signal transduction and other biological processes, and has close correlation with the detection of the imbalance of neurotransmitter levels such as GABA, 5-HT and the like and the change of the number and distribution of Nib bodies in experiments. The myocardial infarction combined anxiety rat hemoglobin complex is obviously reduced, and the heme binding and oxygen binding capacity are reduced. It is suggested that myocardial infarction with more severe anxiety behavior may also be associated with hippocampal hypoxia, reduced hemoglobin levels and related oxidative stress.
In conclusion, the traditional Chinese medicine composition disclosed by the invention can promote myocardial cell repair in myocardial infarction marginal area and improve cardiac function by improving the level of haemoglobin complex in hippocampal area and myocardial tissue and the activity of oxygen carrier and relieving ischemia and hypoxia of tissue.
Example 2: random double-blind placebo parallel control test for treating abnormal coronary heart disease
The efficacy and safety of the Chinese medicinal composition (12 g of bupleurum, 10g of scutellaria baicalensis, 10g of red sage root, 10g of radix curcumae, 16g of poria cocos, 10g of cassia twig and 20g of hypericum perforatum) for treating the double heart disease are observed by adopting a random double-blind placebo parallel control design. The control group adopts cardiovascular conventional medicines matched with anxiolytic depression western medicines, however, most of traditional anxiolytic depression medicines have cardiotoxicity, and the novel anxiolytic depression medicines have the defects of slow effect and increased adverse reaction when being used together with other medicines.
As can be seen from table 3, the angina pectoris curative effect evaluation is carried out on two groups of subjects, the treatment group adopts the traditional Chinese medicine combination formula to intervene and take effect on 12 persons, 18 persons and 2 persons, and the total effective rate is 93.75%; placebo intervention in control group showed 10 persons, 14 persons, 8 persons, and 75% overall efficiency. The total effective rate of the treatment group is superior to that of the control group, and the difference between the two groups has statistical significance (P < 0.05) through chi-square test. The traditional Chinese medicine composition can reduce the duration time and the attack frequency of angina pectoris of a patient with double heart disease, is safe to take, does not have obvious adverse reaction, and has the total effective rate of angina pectoris treatment of 93.75%.
Table 3 comparative n (%)
As can be seen from table 4, the treatment group had a NST of 3.22±0.79 (number) at week 0, the control group had a NST of 3.22±0.66 (number) at week 0, and there was no statistical significance in comparing the differences between the two groups (p=0.879 > 0.05). The NST of the treatment group at week 6 is 1.66+/-0.70 (number), the NST of the control group at week 6 is 3.06+/-0.72 (number), and the difference between the two groups is statistically significant (P=0.000 < 0.05). The relative differences in the treatment groups at weeks 0, 6 weeks NST were statistically significant (p=0.000 < 0.05). Treatment group 0 Zhou ST was 4.41±0.71 (mm), control group 0 Zhou ST was 4.22±0.98 (mm), and the difference between the two groups was not statistically significant (p=0.392 > 0.05). Treatment group 6 weeks Σst was 1.88±0.75 (mm), control group 6 weeks Σst was 3.97±1.00 (mm), and the difference between the two groups was statistically significant (p=0.000 < 0.05). The relative differences in the treatment groups 0 week, 6 weeks Σst were statistically significant (p=0.000 < 0.05). The Chinese medicinal composition can reduce NST and ΣST of patients with double heart diseases.
Table 4 comparison of changes in two sets of resting electrocardiograms NST (in number) and Sigma ST (mm)
As can be seen from table 5, the HAMA scale score significantly decreased after 6 weeks of treatment in the treatment group. The placebo group HAMA scale scores had a decreasing trend, but the differences were not statistically significant, and the comparison of the two groups of differences between groups was statistically significant. The decrease in HAMA scores from week 2 on showed that the test group was superior to the control group, and the difference was statistically significant. The Chinese medicinal composition can improve anxiety state of patients with double heart disease.
TABLE 5 HAMA-14 score for each visit point
As can be seen from table 6, there was no statistical difference in total integrated overall mean of the two groups prior to treatment (t=0.195, p=0.846); after 6 weeks of treatment, the traditional Chinese medicine syndrome score of the treatment group is obviously reduced compared with that before treatment, the total score of the traditional Chinese medicine syndrome score is lower compared with that of a placebo group, and the difference is statistically significant (P < 0.05), wherein 1 treatment group shows 1 case of effectiveness, 31 cases of effectiveness, 1 case of ineffectiveness and 0 case of aggravation. The placebo group had a statistically significant (P < 0.05) decrease in the integral after 6 weeks of treatment and before treatment, with 0 cases with 7 cases with 25 cases with no effect and 2 cases with exacerbations.
Table 6 total integration of the symptoms of TCM before and after treatment
As can be seen from Table 7, after 6 weeks of treatment in the treatment group, both Hs-CRP and IL-6 were decreased, and the intra-group differences were statistically significant (P<0.05 And the decrease was superior to that of the control group, the difference in comparison between groups was statistically significant (P) HS-CRP ＝0.000<0.05；P IL-6 ＝0.009<0.05). The Chinese medicinal composition can reduce hs-CRP and IL-6 level of patients with double heart disease, and reduce vascular endothelial injury by improving inflammation.
TABLE 7hs-CRP, IL-6Horizontal level
Thus, whether animal experiments or clinical experiment index detection fully show that the formula can be used for
Various indexes of the double heart disease model animal can be obviously reduced, and the heart function, emotion and behavior of the model animal can be improved by regulating and controlling the level of the hemoglobin complex and the activity of the oxygen carrier; the Chinese medicinal composition can obviously improve heart and mental symptoms of patients with the double heart diseases, such as chest distress and chest pain, dysphoria, dizziness, bitter taste in chest and hypochondrium, bitter taste in mouth and dry throat, has the effects of resisting inflammation and repairing myocardial cells and neuron cells, and can treat the double heart diseases.
Claims (8)
1. The traditional Chinese medicine composition for treating the double heart disease is characterized by being prepared from the following traditional Chinese medicines in parts by weight: 6-24 parts of bupleurum, 5-20 parts of baical skullcap root, 5-20 parts of danshen root, 5-20 parts of turmeric root-tuber, 8-32 parts of Indian buead, 5-20 parts of cassia twig and 10-30 parts of hyperforin.
2. The Chinese medicinal composition for treating the double heart disease according to claim 1, which is characterized by being prepared from the following Chinese medicaments in part by weight: 6 parts of bupleurum, 5 parts of scutellaria baicalensis, 5 parts of red-rooted salvia root, 5 parts of radix curcumae, 8 parts of poria cocos, 5 parts of cassia twig and 10 parts of hypericum perforatum.
3. The Chinese medicinal composition for treating the double heart disease according to claim 1, which is characterized by being prepared from the following Chinese medicaments in part by weight: 24 parts of bupleurum, 20 parts of scutellaria baicalensis, 20 parts of red-rooted salvia root, 20 parts of radix curcumae, 32 parts of poria cocos, 20 parts of cassia twig and 30 parts of hypericum perforatum.
4. The Chinese medicinal composition for treating the double heart disease according to claim 1, which is characterized by being prepared from the following Chinese medicaments in part by weight: 12 parts of bupleurum, 10 parts of scutellaria baicalensis, 10 parts of red-rooted salvia root, 10 parts of radix curcumae, 16 parts of poria cocos, 10 parts of cassia twig and 20 parts of hypericum perforatum.
5. A method for preparing a Chinese medicinal composition for treating double heart disease according to any one of claims 1 to 4, which is characterized by comprising the following steps: weighing the above medicines according to the weight ratio, adding water which is 5-10 times of the total weight of the medicines for decoction for 1-3 times, combining the decoction and concentrating to 1/3-1/2 of the water adding amount, thus obtaining the traditional Chinese medicine.
6. A medicament for treating double heart disease, which is characterized by comprising the traditional Chinese medicine composition according to any one of claims 1-4 and a pharmaceutically acceptable carrier.
7. The medicament for treating double heart disease according to claim 6, wherein the medicament is an oral preparation or an injection.
8. Use of a Chinese medicinal composition for treating double heart disease according to any one of claims 1 to 4 in the preparation of a medicament for treating double heart disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311044497.2A CN116870121B (en) | 2023-08-18 | 2023-08-18 | Traditional Chinese medicine composition for treating double heart disease and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311044497.2A CN116870121B (en) | 2023-08-18 | 2023-08-18 | Traditional Chinese medicine composition for treating double heart disease and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116870121A true CN116870121A (en) | 2023-10-13 |
| CN116870121B CN116870121B (en) | 2024-04-02 |
Family
ID=88256997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311044497.2A Active CN116870121B (en) | 2023-08-18 | 2023-08-18 | Traditional Chinese medicine composition for treating double heart disease and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116870121B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008019588A1 (en) * | 2006-08-09 | 2008-02-21 | Xiamen Guilong Investment Management Co., Ltd | A chinese medicine composition for treating depression, neurasthenia and process thereof |
| CN104873908A (en) * | 2015-06-13 | 2015-09-02 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating coronary heart disease with anxiety |
| CN108295168A (en) * | 2018-03-12 | 2018-07-20 | 江苏省第二中医院 | A kind of Chinese medicine composition for treating Poststroke Depression |
| CN112156144A (en) * | 2020-11-03 | 2021-01-01 | 中国中医科学院西苑医院 | Traditional Chinese medicine composition, medicine for treating qi deficiency and blood stasis type coronary heart disease with anxiety and depression, and preparation method and application thereof |
| CN112294874A (en) * | 2020-10-23 | 2021-02-02 | 江西普正制药股份有限公司 | Preparation method of pharmaceutical composition and application of pharmaceutical composition in treating diplocardia |
| CN113274471A (en) * | 2021-04-29 | 2021-08-20 | 宋银枝 | Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application |
| CN113925946A (en) * | 2021-11-25 | 2022-01-14 | 回音必集团浙江齐齐制药有限公司 | Traditional Chinese medicine for soothing liver and relieving depression and preparation method thereof |
| CN115252691A (en) * | 2022-08-05 | 2022-11-01 | 长春中医药大学 | Traditional Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease angina |
| CN115429864A (en) * | 2019-11-29 | 2022-12-06 | 王宇红 | Traditional Chinese medicine composition for treating depression |
| US20230125425A1 (en) * | 2019-11-14 | 2023-04-27 | Chenland Nutritionals, Inc. | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof |
| CN116942754A (en) * | 2022-12-21 | 2023-10-27 | 北京中医药大学东方医院 | Composition and preparation for reducing angina pectoris and improving depression degree of coronary heart disease patient |
-
2023
- 2023-08-18 CN CN202311044497.2A patent/CN116870121B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008019588A1 (en) * | 2006-08-09 | 2008-02-21 | Xiamen Guilong Investment Management Co., Ltd | A chinese medicine composition for treating depression, neurasthenia and process thereof |
| CN104873908A (en) * | 2015-06-13 | 2015-09-02 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating coronary heart disease with anxiety |
| CN108295168A (en) * | 2018-03-12 | 2018-07-20 | 江苏省第二中医院 | A kind of Chinese medicine composition for treating Poststroke Depression |
| US20230125425A1 (en) * | 2019-11-14 | 2023-04-27 | Chenland Nutritionals, Inc. | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof |
| CN115429864A (en) * | 2019-11-29 | 2022-12-06 | 王宇红 | Traditional Chinese medicine composition for treating depression |
| CN112294874A (en) * | 2020-10-23 | 2021-02-02 | 江西普正制药股份有限公司 | Preparation method of pharmaceutical composition and application of pharmaceutical composition in treating diplocardia |
| CN112156144A (en) * | 2020-11-03 | 2021-01-01 | 中国中医科学院西苑医院 | Traditional Chinese medicine composition, medicine for treating qi deficiency and blood stasis type coronary heart disease with anxiety and depression, and preparation method and application thereof |
| CN113274471A (en) * | 2021-04-29 | 2021-08-20 | 宋银枝 | Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application |
| CN113925946A (en) * | 2021-11-25 | 2022-01-14 | 回音必集团浙江齐齐制药有限公司 | Traditional Chinese medicine for soothing liver and relieving depression and preparation method thereof |
| CN115252691A (en) * | 2022-08-05 | 2022-11-01 | 长春中医药大学 | Traditional Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease angina |
| CN116942754A (en) * | 2022-12-21 | 2023-10-27 | 北京中医药大学东方医院 | Composition and preparation for reducing angina pectoris and improving depression degree of coronary heart disease patient |
Non-Patent Citations (8)
| Title |
|---|
| 招伟成;张忠;: "桂枝茯苓丸合温胆汤加减联合西医基础治疗对冠心病抑郁状态的影响", 西部中医药, no. 11, 15 November 2019 (2019-11-15), pages 94 - 96 * |
| 朱天翔;方祝元;: "从气血论冠心病伴焦虑症的中医病机及"双心"治疗", 江苏中医药, no. 06, 5 June 2018 (2018-06-05), pages 10 - 12 * |
| 李静;刘亚荣;任得志;朱海慧;王东亮;李婷;: "柴胡加龙骨牡蛎汤治疗冠心病合并抑郁的临床效果", 世界中医药, no. 10, pages 67 - 71 * |
| 王昀;王超;燕莎莎;侯季秋;赵海滨;: "从"双心"探析柴胡加龙骨牡蛎颗粒对冠心病合并焦虑状态的临床研究", 环球中医药, no. 08, 6 August 2017 (2017-08-06), pages 31 - 36 * |
| 王萌;: "邓悦教授运用养心汤加减治疗"双心"疾病", 吉林中医药, no. 06, 20 June 2013 (2013-06-20), pages 553 - 554 * |
| 袁慎洋;周良柱;蒋克浩;杨泗波;于俊俊;卢秋波;黄金银;: "柴胡桂枝汤治疗双心疾病30例", 河南中医, no. 08, 1 August 2017 (2017-08-01), pages 32 - 34 * |
| 道群;: "抑肝散合黛力新治疗双心疾病疗效观察", 中国实用医药, no. 19, 10 July 2014 (2014-07-10), pages 196 - 197 * |
| 黄乐曦，等: "双心方治疗心肌梗死后抑郁的网络药理学研究", 中医学报, vol. 36, no. 9, 31 August 2021 (2021-08-31), pages 1985 - 1991 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116870121B (en) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112717062B (en) | Traditional Chinese medicine composition for treating diabetic retinopathy | |
| WO2022021636A1 (en) | Traditional chinese medicine composition for invigorating spleen and activating collaterals, and use thereof | |
| CN108853258B (en) | Traditional Chinese medicine composition for treating functional constipation and application thereof | |
| CN104147345B (en) | A kind of Chinese medicine composition for treating cardiovascular autonomic neuropathy | |
| CN116870121B (en) | Traditional Chinese medicine composition for treating double heart disease and preparation method and application thereof | |
| CN115487283B (en) | Traditional Chinese medicine preparation for treating heart failure | |
| US20030143289A1 (en) | Herbal composition PHY828 and its use | |
| CN104147346A (en) | Traditional Chinese medicinal compound for treating coronary diffuse lesion angina | |
| CN110292607B (en) | Traditional Chinese medicine composition for treating hypertension complicated with left ventricular hypertrophy and preparation method thereof | |
| CN108295168B (en) | Traditional Chinese medicine composition for treating post-stroke depression | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN110882347A (en) | A Chinese medicinal composition for treating cardiovascular diseases | |
| CN114848775B (en) | Traditional Chinese medicine composition for treating acute myocardial infarction as well as traditional Chinese medicine preparation and application thereof | |
| CN108403803B (en) | Chinese medicinal compound preparation for preventing and treating cardiovascular complications of diabetes | |
| CN116999486B (en) | Zhuang medicine compound medicine for treating ischemic stroke convalescence and preparation method thereof | |
| CN113559206B (en) | Compound traditional Chinese medicine for preventing and treating atrial fibrillation | |
| Han et al. | Summary of Zhang Hongxing's Experience in Treating Refractory Angina Pectoris with Traditional Chinese Medicine | |
| CN1308952A (en) | Chinese medicine for treating trigeminal neuraligia and its preparing process | |
| CN117959362A (en) | Traditional Chinese medicine composition for treating sepsis cardiomyopathy and application thereof | |
| Xiaohan et al. | A Preliminary Study on Fan Xiufeng's Clinical Experience in Treating Chest Arthralgia and Heart Pain with Yang Deficiency and Phlegm and Blood Stasis | |
| CN115177669A (en) | Traditional Chinese medicine composition with effect of treating myocardial bridge and application thereof | |
| CN104645020A (en) | Traditional Chinese medicine composition for treating coronary heart disease and angina and application of traditional Chinese medicine composition | |
| CN110693929A (en) | Application of compound medicine components in treating cerebral infarction recovery period | |
| CN104721411B (en) | A kind of pharmaceutical composition and its preparation method and application for treating anaemia | |
| CN114869928A (en) | Traditional Chinese medicine composition for treating cerebrovascular diseases and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhao Haibin Inventor after: Hou Jiqiu Inventor after: Gao Yaru Inventor after: Sun Zhiqi Inventor after: Gui Yiwei Inventor after: Wang Chao Inventor after: Liu Jingwei Inventor before: Zhao Haibin Inventor before: Hou Jiqiu Inventor before: Gao Yaru Inventor before: Sun Zhiqi Inventor before: Gui Yiwei Inventor before: Wang Chao Inventor before: Liu Jingwei |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |